Vanguard Global Advisers
VNDA icon

Vanguard Global Advisers’s Vanda Pharmaceuticals VNDA Stock Holding History

Vanguard Global Advisers’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149K Sell
24,398
-46,218
-65% -$302K ﹤0.01% 2618
2026
Q1 		$488K Buy
+70,616
New +$545K ﹤0.01% 2062

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's VNDA Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Vanda Pharmaceuticals (VNDA) stake by 65% in Q2 2026, selling an estimated $302K and leaving 24,398 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #2618.

Vanguard Global Advisers first reported a position in VNDA in Q1 2026 and has held it in 2 quarters since. The position peaked at $488K in Q1 2026. 169 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Vanguard Global Advisers held 24,398 shares of Vanda Pharmaceuticals worth $149K as of Q2 2026.
  • Vanguard Global Advisers sold 46,218 Vanda Pharmaceuticals shares in Q2 2026, an estimated $302K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2618 holding.
  • Vanguard Global Advisers first reported a position in Vanda Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Vanda Pharmaceuticals position peaked at $488K in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.